Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
Education Center - SponsoredReclaiming Lost Hours: How Digital Prescription Management Is Reshaping Veterinary Workflowsby • MWI Animal HealthAs administrative burdens grow, digital prescription management offers veterinary teams a path to greater efficiency, fewer errors, and more time for patient care.
